Stratistics MRC¿¡ ÀÇÇϸé, ¼¼°èÀÇ ¿Â¼º ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷(AIHA) ½ÃÀåÀº 2025³â¿¡ 8¾ï 4,200¸¸ ´Þ·¯¸¦ Â÷ÁöÇϰí, ¿¹Ãø ±â°£ Áß¿¡ CAGR 15.2%·Î ¼ºÀåÇÏ¿© 2032³â¿¡´Â 22¾ï 7,600¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¿Â¼º ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷Àº ½ÅüÀÇ ¸é¿ªÃ¼°è°¡ Ç×ü¸¦ »ý¼ºÇÏ¿© Á¤»ó ü¿Â¿¡¼ ÀÚ½ÅÀÇ ÀûÇ÷±¸¸¦ À߸ø °ø°ÝÇÏ¿© ÆÄ±«ÇÏ´Â Èñ±ÍÇÑ Ç÷¾×ÁúȯÀÔ´Ï´Ù. ÀÌ ÆÄ±«·Î ÀÎÇØ ÀûÇ÷±¸ ¼ö°¡ °¨¼ÒÇÏ¿© ºóÇ÷À» À¯¹ßÇÕ´Ï´Ù. Ç×ü´Â ÀϹÝÀûÀ¸·Î IgG °è¿¿¡ ¼ÓÇϸç ÀûÇ÷±¸ Ç¥¸éÀÇ Ç׿øÀ» Ç¥ÀûÀ¸·Î ÇÕ´Ï´Ù. ÀÌ ÁúȯÀº ÀÚ¿¬ÀûÀ¸·Î ¹ß»ýÇϱ⵵ Çϰí, ´Ù¸¥ ÁúȯÀÇ ÀÌÂ÷Àû Áõ»óÀ¸·Î ¹ß»ýÇϱ⵵ ÇÕ´Ï´Ù. Àü¹®ÀûÀÎ Áø´Ü°ú Ä¡·á°¡ ÇÊ¿äÇÕ´Ï´Ù.
º¸°í¼¿¡ µû¸£¸é, ¹Ì±¹Àº ¿Â¼º ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷(WAIHA)ÀÇ °¡Àå Å« ȯÀÚÃþÀ̸ç, ±× Ä¡·á ½ÃÀåµµ °¡Àå Å« ½ÃÀåÀÔ´Ï´Ù.
Èñ±ÍÁúȯ¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í
Èñ±ÍÁúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷ ½ÃÀåÀÇ ¹ßÀüÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿ËÈ£ ´Üü, ÀÇ·á Ä·ÆäÀÎ, Áø´Ü ´É·ÂÀÇ Çâ»óÀ¸·Î Á¶±â ¹ß°ß°ú °³ÀÔÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. Á¤ºÎ¿Í ºñ¿µ¸® ´Üü´Â Àû½Ã Ä¡·áÀÇ Á߿伺À» °Á¶ÇÏ´Â ÀÎ½Ä °³¼± ÇÁ·Î±×·¥¿¡ ÅõÀÚÇÏ¿© ȯÀÚÀÇ Âü¿©¸¦ µ¶·ÁÇϰí Ä¡·á ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á Á¾»çÀÚ¸¦ À§ÇÑ ÀÇ·á ±³À° ÀÌ´Ï¼ÅÆ¼ºê´Â Áø´Ü Á¤È®µµ¸¦ ³ôÀÌ°í ´õ ¸¹Àº ȯÀÚ°¡ ´õ »¡¸® ÀûÀýÇÑ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï ÇÔÀ¸·Î½á ¼±Áø±¹°ú ½ÅÈï±¹ÀÇ ÀÇ·á ½Ã½ºÅÛ Àü¹Ý¿¡ °ÉÃÄ ÀϰüµÈ ¹ßÀüÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
³ôÀº Ä¡·áºñ¿Í ¾àǰºñ
³ôÀº Ä¡·áºñ¿Í ¾àǰºñ´Â ¿©ÀüÈ÷ AIHA ½ÃÀå ¼ºÀåÀÇ Å« À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÷´ÜÄ¡·áÁ¦, ƯÈ÷ »ý¹°ÇÐÀû Á¦Á¦´Â Á¦Á¶ºñ¿ëÀÌ ³ô±â ¶§¹®¿¡ ÁßÀú¼ÒµæÃþ ȯÀÚµéÀÌ ½±°Ô ±¸¸ÅÇÒ ¼ö ÀÖ´Â °¡°Ý¿¡´Â ÇѰ谡 ÀÖ½À´Ï´Ù. ¼±Áø±¹¿¡¼µµ ºñ¿ëºÎ´ãÀÌ Ä¿¼ »óȯÀÇ Á¦ÇÑÀ¸·Î ÀÎÇØ Á¢±ÙÀÌ Á¦ÇѵǴ °æ¿ì°¡ ¸¹½À´Ï´Ù. Ä¡·á°¡ Àå±â°£¿¡ °ÉÃÄ ÁøÇàµÇ±â ¶§¹®¿¡ Àüü Ä¡·áºñ¿ëÀÌ ´õ¿í ´Ã¾î³³´Ï´Ù. °á°úÀûÀ¸·Î ÀÌ·¯ÇÑ °æÁ¦Àû ºÎ´ãÀº Ä¡·á ½ÃÀÛÀ» Áö¿¬½Ã۰í, Ä¡·á ¼øÀÀµµ¸¦ ³·Ã߸ç, ½ÃÀå¿¡¼ »õ·Î¿î Ä¡·á ¿É¼ÇÀÇ Æø³ÐÀº äÅÃÀ» ÀúÇØÇÏ´Â ¿äÀÎÀÌ µË´Ï´Ù.
Ç¥Àû Ä¡·á ¿É¼Ç Á¶»ç
Ç¥ÀûÄ¡·áÁ¦ ¿¬±¸´Â AIHA ½ÃÀå¿¡ À¯¸®ÇÑ ¼ºÀå ¼ö´ÜÀ» Á¦½ÃÇÕ´Ï´Ù. Á¤¹ÐÀÇ·á Á¢±Ù¹ýÀº ¿ëÇ÷¿¡ °ü¿©Çϴ ƯÁ¤ ¸é¿ª °æ·Î¸¦ ´Ù·ç´Â Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ°Ô ÇØÁÖ°í ÀÖ½À´Ï´Ù. ´ÜŬ·Ð Ç×ü, ÀúºÐÀÚ ÈÇÕ¹°, À¯ÀüÀÚ ±â¹Ý Ä¡·á¹ýÀÇ ¹ßÀüÀ¸·Î ºÎÀÛ¿ëÀÌ Àû°í º¸´Ù È¿°úÀûÀÎ Ä¡·á °á°ú°¡ ±â´ëµÇ°í ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ±â¾÷, ¿¬±¸±â°ü, ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü °£ÀÇ Çù·Â °È´Â ÀÓ»ó °Ë»ç¸¦ °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀÇ ¹°°áÀº ȯÀÚÀÇ »îÀÇ ÁúÀ» Å©°Ô Çâ»ó½Ãų ¼ö ÀÖ´Â Â÷¼¼´ë Ä¡·á ÇÁ·ÎÅäÄÝÀ» ¸¸µé¾î ³¾ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.
Àå±â Ä¡·á·Î ÀÎÇÑ ºÎÀÛ¿ë
Àå±â Ä¡·á·Î ÀÎÇÑ ºÎÀÛ¿ëÀº AIHA Ä¡·á µµÀÔ¿¡ Å« À§ÇùÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å, ¸é¿ª¾ïÁ¦Á¦, »ý¹°ÇÐÀû Á¦Á¦ÀÇ Àå±â »ç¿ëÀº °¨¿°, Àå±â µ¶¼º, ´ë»ç ÀÌ»ó µîÀÇ ½É°¢ÇÑ ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÎÀÛ¿ëÀº Á¾Á¾ Ä¡·áÀÇ º¯°æÀ̳ª Áß´ÜÀ» ÇÊ¿ä·Î Çϸç, Ä¡·á È¿°ú¸¦ ¼Õ»ó½Ãŵ´Ï´Ù. QOL(»îÀÇ Áú)¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ȯÀÚ°¡ ¾à¹° º¹¿ëÀ» ²¨¸®´Â °ÍÀº ¾à¹° ¼øÀÀµµ¿¡ ´õ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¶ÇÇÑ, ¸¸¼ºÀûÀÎ Ä¡·á ¿ä¹ý¿¡ ¼ö¹ÝµÇ´Â À§Çè¿¡ ´ëÇÑ ÀνÄÀº ÀÔÁõµÈ È¿°ú¿¡µµ ºÒ±¸ÇÏ°í Æ¯Á¤ ¾à¹° °è¿ÀÇ ÀÓ»óÀû ¼ö¿ëÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
Äڷγª19´Â Áø·á Áö¿¬°ú ÀÇ·á ÀÚ¿øÀÇ ÀçºÐ¹è·Î ÀÎÇØ AIHAÀÇ Áø´Ü°ú Ä¡·á¿¡ ÁöÀåÀ» ÃÊ·¡Çß½À´Ï´Ù. ¸¹Àº ȯÀÚµéÀÌ Áø·á¸¦ ¹Ì·ç¸é¼ Àû½Ã¿¡ Ä¡·á¸¦ ½ÃÀÛÇÏ´Â µ¥ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±×·¯³ª ÀÌ À§±â´Â ¿ø°ÝÀÇ·áÀÇ µµÀÔ¿¡µµ ¹ÚÂ÷¸¦ °¡ÇÏ¿© ¿ø°ÝÁö¿¡¼ ȯÀÚÀÇ ¸ð´ÏÅ͸µ°ú »çÈİü¸®¸¦ °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. COVID °ü·Ã ÀÚ°¡¸é¿ª ¹ÝÀÀ¿¡ ´ëÇÑ Á¶»ç´Â Èñ±Í ÀÚ°¡¸é¿ªÁúȯ¿¡ ´ëÇÑ °úÇÐÀû °ü½ÉÀ» ³ô¿© AIHAÀÇ ¿¬±¸ ÆÄÀÌÇÁ¶óÀο¡ °£Á¢ÀûÀ¸·Î µµ¿òÀÌ µÇ¾ú½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ ¾ÈÁ¤ÈµÊ¿¡ µû¶ó Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÓ»ó °Ë»ç Ȱµ¿ÀÌ È°¹ßÇØÁ® ÆÒµ¥¹Í ÀÌÈÄ ½ÃÀåÀÌ Á¡Â÷ ȸº¹µÇ´Â µ¥ ±â¿©Çß½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¿Â¿ ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷ ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀåÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¿Â¿ ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷Àº ÇÑ·© ÀÀÁý¼Ò Áúȯ¿¡ ºñÇØ ³ôÀº À¯º´·ü·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ºÎ¹®Àº Áø´Ü ±âÁØÀÇ °³¼±°ú ÀÇ»çÀÇ ÀÎ½Ä °³¼±À¸·Î Á¶±â¿¡ Ä¡·á¸¦ ½ÃÀÛÇÒ ¼ö ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦, Ç¥Àû ¸é¿ª¾ïÁ¦Á¦ µî Ä¡·á¹ýÀÇ ¹ßÀüÀ¸·Î °ü¸® ¼º°ú°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áúº´ ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ¿¬±¸°¡ ÁøÇàµÊ¿¡ µû¶ó Ä¡·á ¿É¼ÇÀÌ È®´ëµÊ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ÇコÄÉ¾î ½ÃÀå¿¡¼ ÀÌ ºÎ¹®ÀÇ ¿ìÀ§°¡ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¸®Åö½Ã¸¿ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¸®Åö½Ã¸¿ ºÎ¹®ÀÌ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ³Ä¡¼º AIHA ȯÀÚ °ü¸®¿¡ ÀÖ¾î ÀÔÁõµÈ È¿°ú¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ ¾à¹°ÀÇ Ç¥Àû B¼¼Æ÷ °í°¥ ±âÀüÀº Áö¼ÓÀûÀÎ °üÇØÀ²À» °¡Á®¿Í ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵忡 ¹ÝÀÀÇÏÁö ¾Ê´Â ȯÀڵ鿡°Ô ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯ¿¡ ´ëÇÑ ÀûÀÀÁõ ¿Ü »ç¿ë°ú ÇÔ²² ÀÓ»óÀû Áõ°ÅÀÇ È®´ë°¡ äÅÿ¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀÇ °³¹ßÀº Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í, ºñ¿ë¿¡ ¹Î°¨ÇÑ ½ÃÀå Àüü¿¡ ´ëÇÑ Ä§Åõ¸¦ ÃËÁøÇϸç, ÀÌ ºÎ¹®ÀÇ ¼ºÀå ±Ëµµ¸¦ °ÈÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â Áúº´¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±, Áø´Ü ´É·ÂÀÇ È®´ë µîÀ» ¹è°æÀ¸·Î Çϰí ÀÖ½À´Ï´Ù. Áß±¹, Àεµ, ÀϺ» µîÀÇ ±¹°¡µéÀº Èñ±ÍÁúȯ ¿¬±¸¿Í ȯÀÚ µî·Ï¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎÀÇ Áö¿ø°ú Àú·ÅÇÑ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ µµÀÔÀ¸·Î Ä¡·á Á¢±Ù¼ºÀÌ ´õ¿í Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ±¹Á¦ Á¦¾àȸ»ç¿Í Áö¿ª ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü¿ÍÀÇ Çù¾÷ÀÌ Áõ°¡ÇÏ¸é¼ ´Ù¾çÇÑ È¯ÀÚÃþ¿¡ ´ëÇÑ Ä¡·áÁ¦ º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â ¼±ÁøÈµÈ ÇコÄɾî ÀÎÇÁ¶ó, ÁÖ¿ä Á¦¾à»çÀÇ Á¸Àç°¨, »õ·Î¿î Ä¡·á¹ý µµÀÔ °¡¼ÓÈ µîÀÌ ¹è°æÀÌ µÇ°í ÀÖ½À´Ï´Ù. ³ôÀº Áø´Ü Á¤È®µµ, ³ÐÀº º¸Çè Àû¿ë ¹üÀ§, Ȱ¹ßÇÑ ÀÓ»ó °Ë»ç°¡ ½ÃÀåÀÇ ±Þ¼ÓÇÑ È®ÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀÇ °·ÂÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â Èñ±ÍÁúȯ¿¡ ´ëÇÑ ÀǾàǰÀÇ ½Å¼ÓÇÑ ½ÂÀÎÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ Áö¿ø Ȱµ¿°ú ¿¬±¸ ÀÚ±Ý Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ³ôÀº ¼ºÀå·üÀ» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
According to Stratistics MRC, the Global Warm Autoimmune Hemolytic Anemia Market is accounted for $842 million in 2025 and is expected to reach $2276 million by 2032 growing at a CAGR of 15.2% during the forecast period. Warm autoimmune hemolytic anemia is a rare hematological disorder in which the body's immune system produces antibodies that mistakenly attack and destroy its own red blood cells at normal body temperature. This destruction leads to a reduction in red blood cell count, causing anemia. The antibodies typically belong to the IgG class and target antigens on the red blood cell surface. The condition can occur spontaneously or secondary to other illnesses. It requires specialized medical diagnosis and treatment.
According to the report, the United States has the largest patient pool for warm autoimmune hemolytic anemia (WAIHA) and also represents the largest market for its treatment.
Growing awareness of rare diseases
Growing awareness of rare diseases is catalyzing advancements in the autoimmune hemolytic anemia market. Advocacy groups, healthcare campaigns, and improved diagnostic capabilities are enabling earlier detection and intervention. Governments and non-profits are investing in awareness programs that highlight the importance of timely treatment, encouraging patient engagement and boosting demand for therapies. Additionally, medical education initiatives for healthcare professionals are improving diagnostic accuracy, ensuring more patients receive appropriate treatments sooner, thereby driving consistent market expansion across developed and emerging healthcare systems.
High treatment and drug costs
High treatment and drug costs remain a significant barrier to AIHA market growth. Advanced therapies, particularly biologics, are expensive to produce, leading to limited affordability for patients in low- and middle-income regions. Even in developed nations, the high cost burden often results in restricted access through reimbursement limitations. The long-term nature of treatment further escalates overall expenses. Consequently, this financial strain can delay treatment initiation, reduce adherence rates, and hinder broader adoption of newer therapeutic options in the market.
Research in targeted therapy options
Research in targeted therapy options presents lucrative growth avenues for the AIHA market. Precision medicine approaches are enabling the development of therapies that address specific immune pathways involved in hemolysis. Advancements in monoclonal antibodies, small molecules, and gene-based treatments are promising more effective outcomes with fewer side effects. Increased collaboration between biotech firms, research institutes, and healthcare providers is accelerating clinical trials. This innovation surge is expected to create next-generation treatment protocols that significantly improve patient quality of life.
Side effects from long-term treatments
Side effects from long-term treatments pose a substantial threat to AIHA therapy adoption. Prolonged use of corticosteroids, immunosuppressants, or biologics can lead to severe complications such as infections, organ toxicity, and metabolic disorders. These adverse effects often necessitate treatment modification or discontinuation, undermining therapy effectiveness. Patient reluctance to continue medications due to quality-of-life concerns further impacts adherence. Moreover, the perception of risk associated with chronic treatment regimens can hinder clinical acceptance of certain drug classes despite their proven efficacy.
The COVID-19 pandemic disrupted AIHA diagnosis and treatment due to delayed medical visits and reallocation of healthcare resources. Many patients experienced postponed consultations, impacting timely therapy initiation. However, the crisis also spurred telemedicine adoption, enabling remote patient monitoring and follow-up care. Research into COVID-related autoimmune responses increased scientific interest in rare autoimmune conditions, indirectly benefiting AIHA research pipelines. As healthcare systems stabilized, pent-up demand for treatment and renewed clinical trial activity contributed to the market's gradual post-pandemic recovery.
The warm autoimmune hemolytic anemia segment is expected to be the largest during the forecast period
The warm autoimmune hemolytic anemia segment is expected to account for the largest market share during the forecast period, propelled by its higher prevalence compared to cold agglutinin disease. This segment benefits from improved diagnostic criteria and increased physician awareness, enabling earlier treatment initiation. Therapeutic advancements, including biologics and targeted immunosuppressants, are enhancing management outcomes. Additionally, ongoing research into disease mechanisms is expanding treatment options, solidifying this segment's dominance across global healthcare markets throughout the forecast timeline.
The rituximab segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the rituximab segment is predicted to witness the highest growth rate, influenced by its proven efficacy in managing refractory AIHA cases. The drug's targeted B-cell depletion mechanism offers durable remission rates, making it a preferred choice for patients unresponsive to corticosteroids. Expanding clinical evidence, coupled with off-label use in autoimmune disorders, is fueling adoption. Furthermore, biosimilar development is expected to improve accessibility, enhancing uptake across cost-sensitive markets and strengthening the segment's growth trajectory.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, fuelled by rising disease awareness, improving healthcare infrastructure, and expanding diagnostic capabilities. Countries like China, India, and Japan are investing heavily in rare disease research and patient registries. Government-backed reimbursement policies and the introduction of affordable biosimilars are further enhancing treatment accessibility. Increasing collaborations between international pharma companies and regional healthcare providers are also boosting therapy penetration across diverse patient populations.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by advanced healthcare infrastructure, strong presence of key pharmaceutical players, and accelerated adoption of novel therapies. High diagnostic accuracy, widespread insurance coverage, and robust clinical trial activity support rapid market uptake. Additionally, the region's strong regulatory framework facilitates faster drug approvals for rare diseases. Increasing patient advocacy efforts and research funding are expected to sustain high growth rates throughout the forecast horizon.
Key players in the market
Some of the key players in Warm Autoimmune Hemolytic Anemia Market include AbbVie Inc., Amgen Inc., AstraZeneca, Biogen Inc., Bristol-Myers Squibb Company, Baxter International Inc., Eli Lilly and Company, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Sanofi, and Takeda Pharmaceutical Company Limited.
July 2025: F. Hoffmann-La Roche Ltd introduced a digital health platform integrated with telemedicine to enhance patient monitoring and management for WAIHA, facilitating remote consultations and streamlined prescription processes.
June 2025: Rigel Pharmaceuticals, in collaboration with Pfizer Inc., announced the commercial launch of fostamatinib for WAIHA in Western Europe, following successful Phase III FORWARD trial results showing durable hemoglobin responses.
March 2025: Johnson & Johnson Services, Inc. announced positive interim results from a Phase II/III clinical trial for nipocalimab, a monoclonal antibody for warm autoimmune hemolytic anemia (WAIHA), demonstrating significant improvement in hemoglobin levels in adult patients.